TRISALUS LIFE SCIENCES, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.66 USD | -0.51% |
|
+3.43% | +14.32% |
| May. 07 | TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors | CI |
| May. 01 | TriSalus Life Sciences Obtains $50 Million Debt Facility | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 313.4 | 222.4 | 262.2 | - | - |
| Enterprise Value (EV) 1 | 313.4 | 222.4 | 262.2 | 262.2 | 262.2 |
| P/E ratio | -2.51 x | -1.26 x | -4.54 x | -6.62 x | -8.83 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 12 x | 8.56 x | 5.43 x | 3.88 x |
| EV / Revenue | - | 12 x | 8.56 x | 5.43 x | 3.88 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | -4.39 x | -7.15 x | -8.77 x | -9.9 x |
| FCF Yield | - | -22.8% | -14% | -11.4% | -10.1% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 31,250 | 26,317 | 26,758 | - | - |
| Reference price 2 | 10.03 | 8.450 | 9.800 | 9.800 | 9.800 |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 18.51 | 30.64 | 48.29 | 67.65 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -54.15 | -36.68 | -29.9 | -23.18 |
| Operating Margin | - | -292.53% | -119.69% | -61.9% | -34.26% |
| Earnings before Tax (EBT) 1 | - | -59.03 | -36.68 | -29.9 | -23.18 |
| Net income 1 | -47.19 | -63.28 | -36.68 | -29.9 | -23.18 |
| Net margin | - | -341.83% | -119.69% | -61.9% | -34.26% |
| EPS 2 | -3.990 | -6.730 | -2.160 | -1.480 | -1.110 |
| Free Cash Flow 1 | - | -50.63 | -36.68 | -29.9 | -26.48 |
| FCF margin | - | -273.53% | -119.69% | -61.9% | -39.15% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.721 | 6.436 | 7.355 | 7.968 | 8.887 | 10.14 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -14.12 | -9.53 | -9.208 | -9.152 | -8.789 | - |
| Operating Margin | -246.78% | -148.07% | -125.19% | -114.86% | -98.9% | - |
| Earnings before Tax (EBT) 1 | -35.51 | -9.53 | -9.208 | -9.152 | -8.789 | - |
| Net income 1 | -36.31 | -9.53 | -9.208 | -9.152 | -8.789 | - |
| Net margin | -634.66% | -148.07% | -125.19% | -114.86% | -98.9% | - |
| EPS 2 | -1.560 | -0.7200 | -0.5100 | -0.5000 | -0.4800 | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -50.6 | -36.7 | -29.9 | -26.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.8
USD
Average target price
16
USD
Spread / Average Target
+63.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.32% | 262M | |
| +3.61% | 108B | |
| +11.01% | 104B | |
| +1.28% | 22.33B | |
| -12.79% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -10.46% | 17.64B | |
| +3.82% | 14.05B | |
| +36.53% | 12.51B |
- Stock Market
- Equities
- TLSI Stock
- Financials TriSalus Life Sciences, Inc.